Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Of the 10 ITT subjects for whom AnnAraC was administered in the 2nd line setting, 5 achieved a CR (50%) and 6 achieved a CRc (60%). Of the 13 subjects in the ITT evaluable population that were 1st or 2nd line treatment, 7 achieved a CR (54%) and 8 achieved a CRc (62%). The mDOR for the 9 subjects who achieved a CRc is approximately 7 months and climbing. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting pSTAT3 and other oncogenic transcription factors wh ...